Clinical trial

First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC

NCT05745350

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-03-07

PhasePHASE2

Study timeline

Study start (actual)2024-03-07Date precision: day

Registry last updated2025-02-11

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Small Cell Lung Cancer Extensive Stageunresolved

Interventions

Pembrolizumab, Plinabulin plus Etoposide and PlatinumDRUG

Sponsors & collaborators

Xiaorong Donglead sponsor

Mapped research locations

WuhanHubei, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05745350 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.